Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone585-271-2700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$720,000.00
Profitability
Miscellaneous
Employees44
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable
Vaccinex (NASDAQ:VCNX) Frequently Asked Questions
What is Vaccinex's stock symbol?
Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."
How were Vaccinex's earnings last quarter?
Vaccinex Inc (NASDAQ:VCNX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.10. The firm had revenue of $0.40 million for the quarter. Vaccinex had a negative net margin of 4,740.03% and a negative return on equity of 585.69%. View Vaccinex's Earnings History.
When is Vaccinex's next earnings date?
What price target have analysts set for VCNX?
1 brokers have issued 1-year target prices for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next year. This suggests a possible upside of 343.5% from the stock's current price. View Analyst Price Targets for Vaccinex.
What is the consensus analysts' recommendation for Vaccinex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaccinex.
Has Vaccinex been receiving favorable news coverage?
Headlines about VCNX stock have been trending very positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Vaccinex earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Vaccinex.
Who are some of Vaccinex's key competitors?
Some companies that are related to Vaccinex include Kamada (KMDA), CytomX Therapeutics (CTMX), Seres Therapeutics (MCRB), Galera Therapeutics (GRTX), Satsuma Pharmaceuticals (STSA), Cue Biopharma (CUE), Albireo Pharma (ALBO), Kalvista Pharmaceuticals (KALV), Fulcrum Therapeutics (FULC), GlycoMimetics (GLYC), MannKind (MNKD), Calithera Biosciences (CALA), Neptune Wellness Solutions (NEPT), Xeris Pharmaceuticals (XERS) and Minerva Neurosciences (NERV).
What other stocks do shareholders of Vaccinex own?
Who are Vaccinex's key executives?
Vaccinex's management team includes the folowing people:
- Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 73)
- Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)
- Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)
- Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
- Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45)
When did Vaccinex IPO?
(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
Who are Vaccinex's major shareholders?
Vaccinex's stock is owned by many different of retail and institutional investors. Top institutional investors include MSD Partners L.P. (8.25%) and Oppenheimer & Co. Inc. (0.19%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View Institutional Ownership Trends for Vaccinex.
Which institutional investors are buying Vaccinex stock?
VCNX stock was acquired by a variety of institutional investors in the last quarter, including MSD Partners L.P. and Oppenheimer & Co. Inc.. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View Insider Buying and Selling for Vaccinex.
How do I buy shares of Vaccinex?
Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vaccinex's stock price today?
One share of VCNX stock can currently be purchased for approximately $4.96.
How big of a company is Vaccinex?
Vaccinex has a market capitalization of $73.72 million and generates $720,000.00 in revenue each year. The company earns $-29,520,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Vaccinex employs 44 workers across the globe.View Additional Information About Vaccinex.
What is Vaccinex's official website?
How can I contact Vaccinex?
Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]
MarketBeat Community Rating for Vaccinex (NASDAQ VCNX)
MarketBeat's community ratings are surveys of what our community members think about Vaccinex and other stocks. Vote "Outperform" if you believe VCNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
